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Abstract 
Treatment regimens for primary central nervous system lymphoma (PCNSL) include high-dose methotrexate (HD-
MTX)-based chemotherapy, with or without radiotherapy and are based on studies of selected patient groups. This 
retrospective study assessed a consistent strategy of response-adapted protocol applied for patients including age 
>65 years in a cancer center for 10 years longitudinally. Case notes were studied of 61 consecutively treated patients 
with PCNSL histologically diagnosed between 2003 and 2013. Clinical follow-up during and after treatment included 
neurologic examination and magnetic resonance imaging. Of the patients studied, 14.8 % (9/61) were clinically 
unfit for chemotherapy; the remaining 85.2 % (52/61) of patients were treated with HD-MTX. Of these patients, 58 % 
(30/52) achieved an initial complete response, with a median survival of 100.1 months. Of these response-adapted 
patients, 33 % (10/30) were <65 years and were treated with upfront high-dose chemotherapy and autologous 
stem-cell transplantation (HDC-ASCT). The remaining response-adapted patients included 53 % (16/30) who were 
≥65 years underwent consolidation with HD-MTX, and 14 % (4/30) who chose radiotherapy. The median survival of 
patients with HDC-ASCT had not yet been reached compared with 67.6 months for patients with HD-MTX consolida-
tion treatment (p = 0.26). At the end of the study, 75 % (39/52) of patients had died mainly owing to progression or 
relapse of PCNSL. Multivariate analysis showed that age younger than 65 years (p = 0.02) and complete response for 
up-front HD-MTX (p = 0.001) were independent prognostic indicators of overall survival. In conclusion, this single-
center retrospective clinical study has shown that treatment of PCNSL with upfront HDC-ASCT and consolidation 
phase HD-MTX monotherapy may be feasible, even for elderly patients in a routine clinical setting, using the three-
step selection by eligibility and response to initial HD-MTX, and age threshold of 65 years for ASCT.
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Background
Primary central nervous system lymphoma (PCNSL) is 
a rare form of extra-nodal lymphoma that accounts for 
approximately 0.8–6.6  % of primary intracranial neo-
plasms (Deckert and Paulus 2007). Ninety-five percent of 
PCNSL are diffuse large B-cell lymphoma (DLBCL) (Deck-
ert and Paulus 2007). PCNSL affects all ages, with a peak 
incidence, in immunocompetent subjects, during the sixth 
and seventh decades of life (Deckert and Paulus 2007). 
Histologically, PCNSL may be low-grade or high-grade, 
with the histological grade reflecting biological aggressive-
ness. The optimal treatment strategy for newly diagnosed 
PCNSL remains controversial, and long-term, disability-
free survival remains poor (Weller et al. 2012; Morris et al. 
2013; Wen 2012; Ponzoni et al. 2014). The poor prognosis 
in PCNSL is particularly found in patients over the age of 
60 years, who comprise the majority of cases.
Current treatment regimens for PCNSL include high-
dose methotrexate (HD-MTX)-based chemotherapy 
with or without radiotherapy. Previously, whole brain 
radiation therapy (WBRT) had played the most impor-
tant role achieving median survival time between 11 
and 18  months (Shibamoto et  al. 2014; Nelson et  al. 
1992). The addition of chemotherapy with HD-MTX 
has resulted in patient survival beyond 30 months (Glass 
et al. 1996; O’Brien et al. 2006). However, both HD-MTX 
and WBRT, individually and in combination, are associ-
ated with acute and long-term neurotoxicity and cogni-
tive dysfunction, which are more common in patients 
who are older than 60 years (Abrey et al. 1998).
Although it is acknowledged that HD-MTX-based 
chemotherapy improves patient survival in PCNSL, the 
optimal chemotherapy regimen, the role of WBRT and 
feasibility of high-dose chemotherapy with autologous 
stem-cell transplantation (HDC-ASCT) rescue are less 
well defined (Hoang-Xuan et al. 2015). The evidence for 
patient treatment regimens is based on studies in highly 
selected groups of patients. However, many patients do 
not meet the selection criteria of clinical trials, as they 
are often elderly with poor performance status, impaired 
cognitive function and rapid neurological progression. 
In clinical practice, prompt treatment decisions are 
required to prevent irreversible deterioration. Therefore, 
elderly patients have been hardly included in randomized 
clinical trials. Poor patient survival in PCNSL has many 
causes, including ineligibility for systemic therapy, bio-
logical resistance to initial therapies, acute and long-term 
adverse events, and frequent relapses that may be refrac-
tory to second-line treatments. There are few studies on 
response-adapted treatment with upfront HDC-ASCT 
rescue or consolidation HD-MTX for patients of all ages 
with PCNSL in routine clinical setting, and length of fol-
low-up after primary treatment has yet to be defined.
In our clinical center, a three-stage intent-to-treat 
strategy for patients of all ages with PCNSL has been 
used consistently for more than 10  years. This three-
stage response-adapted treatment strategy includes 
upfront HD-MTX followed by HDC-ASCT rescue or 
consolidation phase HD-MTX treatment. This retro-
spective clinical study was undertaken to determine 
whether this response-adapted treatment strategy 
is feasible and whether it contributes to survival of 




We examined the records of 61 consecutive patients with 
primary central nervous system lymphoma (PCNSL), 
diagnosed between June 2003 and May 2013 at our insti-
tution. Patient data were collected in June 2015. The 
Institute Review Board approved the study protocol and 
patient treatment protocols.
All patients included in this study had a histological 
diagnosis of PCNSL. All patients had a staging evalua-
tion before treatment. Investigations included gadolin-
ium-enhanced magnetic resonance imaging (MRI) of the 
brain and spinal cord and computed tomography (CT) 
scans of the chest, abdomen and pelvis, creatinine clear-
ance, and human immunodeficiency virus (HIV) testing. 
Patients underwent lumbar puncture, ultrasonic exami-
nation of the testes, bone marrow biopsy, and fluorode-
oxyglucose-positron emission tomography (FDG-PET) 
imaging. A slit-lamp ophthalmologic examination was 
carried out routinely.
Treatment strategy (Fig. 1)
The following three-stage patient selection process was 
used:
Selection Step 1: Eligibility for initial HD-MTX. 
Throughout the study period, all patients received 
treatment with HD-MTX as their initial treatment, 
if they were eligible for treatment. If a patient was 
considered unfit to tolerate HD-MTX on the basis 
of poor performance status and/or systemic compli-
cations, the patient underwent WBRT or palliative 
therapy.
Selection Step 2: Response to the initial HD-MTX. We 
set response-adapted treatments. For patients who 
achieved a complete response (CR) from the initial 
HD-MTX, the intention was that they should proceed 
to consolidation chemotherapy deferring WBRT. For 
patients who had a partial response (PR) or progres-
sive disease (PD), WBRT was recommended.
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Selection Step 3: Consolidation regimen by patient 
age. Patients with intention-to-treat using chemo-
therapy-alone were subdivided to HDC-ASCT rescue 
for patients under 65 years of age and HD-MTX con-
solidation therapy for patients who were 65 years and 
older.
HD‑MTX monotherapy and response‑adapted therapy
HD-MTX (at a dose of 3.5  g/m2 intravenously over 6  h 
on day 1) with calcium folinate rescue was repeated every 
2  weeks for a maximum of six cycles. Patients received 
corticosteroid (betamethasone) at a dose of 2 mg/day in 
day 1 of each course, and in day 1 of following courses if 
clinically indicated.
The HD-MTX dose was adjusted according to the 
patient’s creatinine clearance measurements. MTX 
was injected into CSF through an Ommaya reservoir 
intra-ventricular catheter system or via lumbar punc-
ture once a week between cycles of HD-MTX. If the 
brain biopsy specimen showed CD20-positive B-lym-
phocytes, patients received rituximab 375 mg/m2 for a 
maximum of six doses between the weeks of HD-MTX 
therapy.
Patients who had a CR with HD-MTX were assigned 
to one of two chemotherapy-alone treatments according 
to their age (Selection Step 3). Patients under 65 years of 
age without systemic disease underwent HDC-ASCT; 
patients over 65 years of age were treated with HD-MTX 
at a dose of 1  g/m2 once every 2  months on four occa-
sions (Fig. 1). If a patient had PD or PR after the second 
or fourth course of HD-MTX, the patient proceeded to 
WBRT at 40 to 50 Gy.
Upfront HDC‑ASCT
G-CSF was used for mobilization of peripheral blood 
progenitor cells after the hyper-CVAD/MA protocol 
during bone marrow recovery. High-dose chemother-
apy before ASCT included one of three regimens: ICE 
(ifomide, carboplatin, etoposide), MCEC (ranimustine, 
carboplatin, etoposide, cyclophosphamide), or MEAM 
(ranimustine, cytarabine, etoposide, melphalan) (Wilson 
et  al. 1992; Imai et  al. 2005; Abrey et  al. 2003; Takasaki 
et al. 2013).
Patient follow‑up
All patients were followed-up clinically after treatment 
with a neurologic examination and gadolinium-enhanced 
MRI. Patients were examined at least once a month using 
MRI during initial HD-MTX therapy. Patients were eval-
uated every 2 months during the first 2 years, and then 
every 3 months for a year, and every 4–6 months for at 
least years, for a total of 10  years after initial therapy. 
Treatment of recurrent PCNSL utilized re-challenge with 
HD-MTX monotherapy, administration of carboplatin 
and etoposide, administration of alkylating chemother-
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(n=9)























Fig. 1 Treatment schema and distribution of patients. AE adverse events, CR complete response, HD-MTX high-dose methotrexate, HDC high-dose 
chemotherapy, ASCT autologous stem-cell transplantation, PD progressive disease, PR partial response, RTX rituximab, WBR whole brain radiotherapy
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Response to treatment was recorded as follows: CR 
was defined as the absence of enhanced lesions or bright 
lesions of diffusion-weighted MR images and no ocular 
involvement by lymphoma; PR was defined as a 50 % or 
more decrease in size of lesions on MR images; PD was 
defined as neurological deterioration or 25  % or more 
increase in size of lesions or any new lesions on imag-
ing. Patients with recurrent disease following CR under-
went thorough diagnostic and staging evaluation again, 
and received chemotherapy, WBRT, or palliative therapy 
according to their neurologic and systemic conditions 
and previous history of treatment.
Statistical analysis
The date of diagnosis was taken as the date of the diag-
nostic biopsy or surgical tumor excision. The date of any 
relapse after CR was recorded along with details of fur-
ther treatment and the date and cause of death. For eval-
uation of delayed neurotoxicity, the global functionality 
of patients was quantified with Karnofsky performance 
score (KPS). Cox proportional hazard model was applied 
to assess the strength of association as for overall sur-
vival (OS). The analyzed variables included patient age, 
gender, eligibility for initial HD-MTX, CR by initial HD-
MTX treatment, the Memorial Sloan Kettering Cancer 
Center (MSKCC) prognosis score, and the International 
Extranodal Lymphoma Study Group (IELSG) prognosis 
score. The OS was defined as the time from diagnosis 
to death from any cause. Progression-free survival (PFS) 
was defined as the time from diagnosis to first documen-
tation of disease progression on imaging or death from 
lymphoma. Survival times were calculated using the 
Kaplan–Meier method, and survival curves were com-
pared using the log-rank test. The level of significance 
(p) was 0.05. Results were analyzed using commercially 




Between June 2003 and May 2013, 61 patients (38 men 
and 23 women) were newly diagnosed with PCNSL 
(Table  1). The median age at diagnosis was 69  years 
(range 42–80  years), only three patients (4.9  %) were 
under 50  years of age. Fifty-eight tumors were high-
grade, diffuse large B-cell lymphoma (DLBCL), and 
three were diagnosed as high-grade lymphoma with no 
specific phenotype. All patients had parenchymal brain 
involvement by primary lymphoma. Concomitant ocu-
lar involvement was detected by slit-lamp examination 
in two patients. All patients were immunocompetent and 
negative for HIV serology. The median OS estimated for 
Table 1 Characteristics of the patients according to accomplished first-line treatment
KPS Karnofsky performance status, MSKCC Memorial Sloan Kettering Cancer Center, IELSG International Extranodal Lymphoma Study Group, HD-MTX high-dose 
methotrexate, HDC-ASCT high-dose chemotherapy with autologous stem cell transplant, WBR whole brain radiotherapy, CR complete response, PR partial response, 
PD progressive disease
Characteristics All Elidible to initial HD‑MTX Non‑eligible
HDC‑ASCT HD‑MTX consolidation HD‑MTX + WBR WBR alone or palliation
Total number 61 10 16 23 9
Gender (man:woman) 38:23 8:2 9:7 14:9 5:4
Age (years) median (range) 69 (42–80) 57 (46–62) 72 (55–80) 66 (42–79) 74 (70–79)
KPS (%) median (range) 60 (30–100) 60 (40–90) 60 (40–90) 50 (30–100) 30 (30–40)
MSKCC
 Class I 3 2 0 1 0
 Class II 20 4 8 7 0
 Class III 38 4 8 15 9
IELSG score
 0 & 1 11 3 4 4 0
 2 & 3 32 6 10 12 1
 4 & 5 18 1 2 7 1
Response to HD-MTX
 CR 30 10 16 4 –
 PR 7 0 0 7 –
 PD 12 0 0 12 –
WBR number 29 0 0 23 6
Median dose (range) 50 (30–59.4) – – 50 (40–59.4) 40 (30–50)
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the entire study population was 41.6  months (95  % CI 
21.1–67.6 months), and the median PFS was 27.9 months 
(95 % CI 14.7–38 months) (Fig. 2a, b). When grouped by 
age, patients between 50 and 59 years had a median sur-
vival of 116.5 months (95 % CI 21.1 months, upper limit 
unavailable at the time of observation). Patients 70 years 
or older had a shorter median OS of 14.4 months (95 % 
CI 5.4–30.2 months) (log rank p < 0.0001).
First‑line treatments
Fifty-two of 61 patients (85.2  %) were eligible for and 
received initial HD-MTX chemotherapy (Selection Step 
1). Forty patients received HD-MTX in combination 
with rituximab (Fig.  1). Fifty patients received intrathe-
cal injection of MTX. Of the 52 patients treated with 
HD-MTX, 41 patients (78.8 %) completed an initial three 
to six cycles of HD-MTX. Thirty (73.2 %) of 41 patients 
achieved CR, and 26 of these patients were given further 
consolidation treatment with chemotherapy alone, defer-
ring WBRT (Selection Step 2). Ten patients proceeded 
to HDC-ASCT, and 16 patients had HD-MTX consoli-
dation therapy according to their age (Selection Step 3). 
Four of 30 patients with CR chose WBRT for their con-
solidation therapy.
All patients with CR rapidly improved in their levels of 
consciousness and focal neurological deficits during the 
first course of HD-MTX. After completion of the initial 
treatment, two patients with CR had mild residual neuro-
logic signs, including one patient with a dystonic posture 
of the left fingers, and another patient with mild hemipa-
resis. Seven (17.1 %) of 41 patients achieved PR, and they 
underwent WBRT. Fifteen (28.8 %) of 52 patients failed to 
respond to the initial HD-MTX therapy; 12 patients with 
PD immediately proceeded to WBRT, and three patients 
received palliative care. Nine of 61 patients (14.8 %) were 
considered unfit to undergo HD-MTX therapy at Selec-
tion Step 1 because of poor performance status, severe 
cardiac compromise, advanced renal failure or hepatic 
failure. Six of these patients received WBRT, and three 
received palliative care.
Figure  3a shows the number of patients and their eli-
gibility for initial HD-MTX therapy by age group. The 
ineligible patients were all over 70 years of age. The per-
centage of patients with CR following initial HD-MTX 
decreased in the elderly patient group. However, more 
than 50 % of the patients in the seventh and eighth dec-
ades of life responded well to treatment (Fig.  3b). Fifty-
two patients, who were eligible for initial HD-MTX, 
showed an increased median OS of 54.1 (95 % CI 30.7–
100.1  months) compared with nine patients who were 
ineligible for HD-MTX, with a median OS of 13.3 months 
(95 % CI 1.2–27.5 months) (log-rank p < 0.0001) (Fig. 3c). 
Patients with CR had a median OS of 100.1 months (95 % 
CI 55.4 months, upper limit is not available), which was 
longer than the OS of patients with PR or PD (log-rank 
p < 0.0001) (Fig. 3d).
When sub-divided according to treatment group, 
26 patients treated with chemotherapy alone showed 
an increase in median OS to 80.6  months (95  % CI 
54.1 months, upper limit is not available) compared with 
patients who received HD-MTX plus WBRT (log-rank 
p = 0.0037) (Fig. 4a). Kaplan-Meier survival curves of ten 
patients with upfront HDC-ASCT had not yet reached 
to its median value, and 16 with HD-MTX consolida-
tion therapy had a median OS of 67.6 months (95 % CI 
30.2  months, upper limit is not available) (log-rank 
p  =  0.2648) (Fig.  4b). Cox-proportional hazard model 
showed that age younger than 65  years (p  =  0.02) and 
a b
Fig. 2 Kaplan–Meier curves of all patients. a Kaplan–Meier curve shows the median overall survival (OS) of all patients is 41.6 months (95 % CI 
21.1–67.6 months). b Kaplan–Meier curve shows the median progression-free survival (PFS) of 27.9 months (95 % CI 14.7–38 months)
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complete response for up-front HD-MTX (p  =  0.001) 
were the independent factors of overall survival (Table 2).
Early toxicity of first‑line chemotherapy
Of the 52 patients who received HD-MTX therapy, only 
one patient experienced Common Terminology for 
Adverse Events Adverse Event (CTCAE) grade-4 heart 
failure, and he died of lymphoma progression within 
2  months following the start of HD-MTX. Otherwise, 
most patients occasionally showed CTCAE grade-1 or 
-2 diarrhea, mild oral irritation, or peripheral edema. For 
patients treated with HDC-ASCT, CTCAE grade-3 tox-
icities included febrile neutropenia in seven patients and 
sepsis in two patients. All patients recovered following 
additional treatments for these side effects.
Relapses and cause of death
Twenty-three patients presented with relapse of lym-
phoma, ten after CR following WBRT and 13 after CR 
following chemotherapy alone. Twelve of 23 patients 
(52.2 %) relapsed within 2 years following initial diagnosis 
of PCNSL. At the first relapse, seven patients underwent 
HD-MTX rechallenge, other five underwent different 
chemotherapy regimens, five underwent WBRT, and six 
went to best supportive care. Three patients developed 
extra-CNS lymphoma, presenting after long follow-up. 
a Eligibility for HD-MTX: Age
Number
b Response for HD-MTX : Age
Age (years) Age (years)
Eligible 















0 24 48 72 96 120 144
Time
-- Eligible (n=52) 
-- Not Eligible (n=9) 
-- CR (n=30) 
-- PR or PD (n=21) 
c OS: Eligibility to HD-MTX d OS: Response to HD-MTX
Fig. 3 Eligibility and responses for HD-MTX. a Age distribution of patients and eligibility for HD-MTX. For initial HD-MTX therapy, 85.2 % patients 
were eligible (white), and nine were unfit for treatment (black). b In total, 57.7 % patients achieved a complete response (light gray), and 22 other 
responses (dark gray) for initial HD-MTX. c Kaplan–Meier estimate of overall survival by eligibility for initial HD-MTX. Median survival for patients 
eligible for treatment was 54.1 months (95 % CI 30.7–100.1 months) compared with 13.3 months (95 % CI 1.2–27.5 months) for those not eligible 
(Log rank p < 0.0001). d Kaplan–Meier estimate of overall survival by the response to the initial HT-MTX. Median survival for patients with complete 
response was 100.1 months (95 % CI 55.4 months to upper limit not available), compared with those with other responses 15.2 months (95 % CI 
4.5–41.6 months (Log rank p < 0.0001). HD-MTX high-dose methotrexate, CR complete response, PR partial response, PD progressive disease, OS 
overall survival
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One patient had lymphoma presenting in the skin at 
37 months, one patient developed intestinal lymphoma at 
54 months, and another patient developed testicular lym-
phoma at 97 months.
Thirty-nine (63.9  %) patients died during the study. 
The cause of death was determined in 38 of 39 patients. 
Thirty patients out of 39 (76.9 %) died as a result of lym-
phoma. Four patients died from infection associated with 
moderate to severe neurological deficits after treatment. 
Two patients died of intracerebral hemorrhage 4 and 
90 months after CR following WBRT. Two patients died 
of causes unrelated to their lymphoma: one of hepatocel-
lular carcinoma after HD-MTX combined with WBRT, 
and another of anorexia nervosa after HD-MTX con-
solidation therapy. One patient suffering from lung can-
cer was cured, and another survived prostate cancer; 
both patients had received treatment for PCNSL with 
HDC-ASCT.
-- HDC-ASCT (n=10) 
-- MTX Consolidation (n=16) 
a OS: Treatment Groups b OS: Chemotherapy Alone
-- Chemotherapy alone (n=26) 
-- HD-MTX + WBR (n=23) 
c d
Fig. 4 Kaplan–Meier estimate of overall survival according to initial treatment groups. a Patients treated with chemotherapy alone had a median 
overall survival 80.6 months (95 % CI 54.1 months to upper limit not available) compared with patients received HD-MTX + WBR 38.7 months (95 % 
CI 9.1–59.3 months) (Log rank p = 0.0037). b Of 26 patients treated with chemotherapy alone, ten patients underwent HDC-ASCT and 16 received 
HD-MTX consolidation. Patients treated with HDC-ASCT showed a survival curve that did not reach the median; patients treated with HD-MTX 
consolidation had a median overall survival 67.6 months (95 % CI 30.2 months to upper limit not available) (Log rank p = 0.2618). c Karnofsky Per-
formance Score of the patients at the last follow-up. More than half of the patients treated with HDC-ASCT presented with 80–100 % KPS (red).  
d Distribution of KPS by age groups. Twenty-two patients were alive longer than 2 years, and 10 (45.5 %) of 22 patients had returned to their normal 
lives with a KPS of 80–100 %. WBR whole brain radiotherapy, OS overall survival, KPS Karnofsky performance status, HD-MTX high-dose methotrexate, 
HDC-ASCT high-dose chemotherapy with autologous stem-cell transplant, MTX methotrexate
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Survivors and performance scores
The 1-year patient survival rate was 75.4  %, and the 
2-year survival rate was 60.7  % for all patients. Of the 
total patients studied, 36.1  % (22/61) survived with a 
median follow-up of 59.7  months. The patient survivor 
group included 70 % (7/10) of the patients who received 
HDC-ASCT; 56.2 % (9/16) of patients treated with HD-
MTX consolidation and 23.1 % (6/23) of patients treated 
with HD-MTX combined with WBRT (Fig. 4c).
Of the 22 survivors of the study, the median Kar-
nofsky performance status (KPS) was 70  %, with a KPS 
of 80–100 % in 45.5 % (10/22) of patients (Fig. 4d). The 
younger the patients were, the better the KPS. Six of the 
seven survivors (71.4  %) who received HDC-ASCT had 
returned to work and had a KPS of between 90–100 %.
Discussion
The median OS of the 61 patients who were included in 
this study was 41.6  months. The OS of patients in this 
study is supported by the results of other published series 
using HD-MTX with or without WBRT for unselected 
patients with PCNSL where median OS values have been 
reported as between 8 and 42  months (Hodson et  al. 
2005; Silvani et  al. 2007; Kiewe et  al. 2008; Muirhead 
et al. 2013; Hart et al. 2014). In our intent-to-treat patient 
population, the patients in their seventh decade had a 
median OS of 67.6 months, and patients in their eighth 
decade had the shortest median OS of 14.4  months. 
Multivariate analysis supported significant effects of 
age under 65  years and CR by initial HD-MTX therapy 
on survival time. Those two factors had been applied in 
selection steps of treatments for our patients consistently.
In this study, patients who responded to chemother-
apy had a longer survival time than those who did not 
(Table  2). Those chemo-sensitive patients might receive 
benefits from HD-MTX alone or upfront HDC-ASCT 
strategy. Two different treatments were selected for 
patients who achieved CR according to age below or 
above 65 years at Selection Step 3: HDC-ASCT and HD-
MTX consolidation therapy. Patients who received HDC-
ASCT had the longest survival in our case series, with a 
2-year and 5-year survival rate of 100 and 80 % respec-
tively. With chemotherapy alone, patients with a median 
age of 72 years received consolidation HD-MTX mono-
therapy and had a median OS of 67.6 months.
Previously published results of studies using upfront 
HDC-ASCT treatment in PCNSL have been encourag-
ing and also support our findings (Illerhaus et  al. 2008; 
Alimohamed et al. 2012; Kiefer et al. 2012; Schorb et al. 
2013). In our study, upfront HDC-ASCT resulted in 
5-year survival rates that compared well with previously 
reported 5-year survival rates of between 44 and 87  % 
(Illerhaus et  al. 2008; Alimohamed et  al. 2012; Schorb 
et al. 2013). Further, in our study there was no observed 
mortality related to treatment toxicity with HDC-ASCT. 
Although HDC-ASCT is the standard treatment for a 
chemo-sensitive systemic relapse in DLBCL without 
CNSL involvement, the role of HDC-ASCT for treatment 
of relapsed or refractory PCNSL remains unclear (Abrey 
et al. 2003). However, because of the risk of toxicity asso-
ciated with HDC-ASCT, this treatment may be indicated 
to younger patients without co-morbidity and admin-
istered in specialized centers with experience in using 
ASCT as therapy.
In this study, we selected patients 65 years or older for 
HD-MTX consolidation treatment after achieving a CR 
in Selection Step 3. Cobert and colleagues have reported 
an excellent clinical outcome following HD-MTX mono-
therapy in patients with PCNSL who had a median age of 
62 years (range 23–86 years) (Cobert et al. 2010). These 
investigators reported treatment regimes of 8 g/m2 MTX 
on an average of 11 cycles, which resulted in a median OS 
of 84 months (Cobert et al. 2010). In our study, patients 
treated with HD-MTX as part of their consolidation 
therapy were older than patients in this previous report, 
received a lower dose and fewer cycles of MTX, and still 
had a comparable median OS of 67.6 months. However, 
the optimal treatment dose and timing of MTX injec-
tions in the treatment of PCNSL are still unknown.
Patients over the age of 65 years can be candidates for 
HD-MTX therapy with proper oncological care from an 
experienced medical team after a thorough evaluation 
of their physical condition. Ghesquieres and colleagues 
reported that age, clinical performance status, and tumor 
site lost their prognostic significance after 6  months 
Table 2 Multivariate analysis of  parameters associated 
with overall survival





 Women versus men 1.321 0.652–2.622 0.432
Age
 Over 65 versus under 65 2.721 1.157–6.671 0.0216*
HD-MTX eligibility
 Eligible versus non-eligible 0.873 0.359–2.205 0.768
Response to HD-MTX
 CR versus others 0.140 0.053–0.343 0.001*
MSKCC class
 1 & 2 versus 3 0.504 0.202–1.186 0.118
IELSG score
 0 to 3 versus 4 & 5 1.13 0.501–2.555 0.766
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of treatment in their series of 91 patients with PCNSL 
(Ghesquieres et  al. 2013). Our results in older patients 
with PCNSL support the conclusions of these previous 
studies, that older patients with poor clinical perfor-
mance status and brain involvement by lymphoma are at 
risk of early death, but a favorable long-term outcome is 
still possible following treatment.
In the 10  years from 2003, the intention at our clini-
cal center had been to use a consistent treatment regime 
for patients diagnosed with PCNSL. Initial HD-MTX 
monotherapy was followed by a response-adapted chem-
otherapy-alone strategy of HDC-ASCT or HD-MTX 
consolidation deferring WBRT. The treatment decision 
for each patient was conducted using a three-step selec-
tion process. A favorable outcome was seen in some 
patients treated with chemotherapy alone, which sup-
ports our use of a step-wise patient treatment selection 
process that increases survival of patients with chemo-
sensitive PCNSL. In a few previously reported single 
center studies, the patients who were eligible for treat-
ment with HD-MTX showed a median OS of between 
40 and 54 months with or without radiotherapy (Cobert 
et al. 2010; Makino et al. 2014). An early CR at the second 
cycle of intensive chemotherapy was a prognostic factor 
in a previously reported study (Pels et al. 2010). Comple-
tion of at least three cycles of HD-MTX-based chemo-
therapy was of prognostic significance in another study 
(Makino et al. 2014). These reports indicate that chemo-
sensitivity is an important prognostic factor for patients 
with PCNSL. Our study supports the view that chemo-
sensitivity can be assessed during but not before chem-
otherapy. Markers for chemo-sensitivity are required 
before commencing HD-MTX or intense chemotherapy, 
because of treatment-associated morbidity and mortality.
Relapse of lymphoma, both early and delayed, remains 
a major problem in the treatment of PCNSL, including in 
this study. The main cause of death of our patients with 
PCNSL was relapse or progression of lymphoma. In this 
series, 52.2 % of cases of relapse occurred within 2 years, 
and late relapse occurred during follow-up after 8 years 
at most. In the literature, the majority of the recurrences 
in PCNSL are reported to develop within 2  years after 
first-line treatment (Jahnke et al. 2006; Nayak et al. 2011). 
These results support the view that intensive clinical 
follow-up should continue for at least 2  years following 
treatment. Treatment toxicity should also be assessed at 
both early and late follow-up, especially neurotoxicity 
and secondary neoplasms.
We had treated elderly patients with PCNSL with our 
chemotherapy-alone strategy for 10  years with accept-
able morbidity. Pre-treatment morbidity has previously 
precluded elderly patients from commencing potentially 
curative treatment. Attempts to reduce toxicity without 
compromising efficacy must address three immediate 
issues: reliable markers for chemo-sensitivity to initial 
HD-MTX, the optimum regimen to increase ratio of CR 
following initial chemotherapy, and the optimum consol-
idation regimen in patients who achieved CR following 
HD-MTX. Multicenter randomized controlled clinical 
trial data is awaited to address these questions.
The present study has limitations that are inherent in a 
retrospective clinical analysis and in this rare and aggres-
sive disease. These limitations include a relatively small 
study population. A detailed and consecutive evaluation 
of cognitive function was not included. All patients were 
sequentially incorporated into the study, and no control 
patients were available.
Conclusions
In conclusion, this single-center retrospective clinical study 
has shown that treatment of PCNSL with upfront HDC-
ASCT and consolidation phase HD-MTX monotherapy 
may be feasible, even for elderly patients in a routine clini-
cal setting, using the three-step selection by eligibility, 
response to HD-MTX, and age threshold of 65  years for 
ASCT. Long-term follow-up of patients treated for PCNSL 
is necessary to assess relapse of lymphoma, or develop-
ment of neurotoxicity and other malignancy.
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